Abstract:
BACKGROUND:This study was performed to determine whether the use of ovulation induction drugs in treatment of infertility have a significant effect on the risk of breast cancer. PATIENTS AND METHODS:This case control study (928 cases, 928 controls), was performed in the gynecology and oncology clinics of Shahid Beheshti University of Medical Sciences between 2011 and 2013. Data were collected via in-person interviews using a questionnaire, which included demographic and gynecologic information. Statistical analysis was performed using SPSS statistics software version 20 (IBM Corp). RESULTS:The use of ovulation induction drugs was not significantly associated with an increased risk of breast cancer (odds ratio [OR], 1.13; 95% confidence interval [CI], 0.7-1.855) among women with infertility (OR, 1.28; 95% CI, 0.8-1.95). CONCLUSION:We observed no statistically significant relationship between infertility and ovulation induction drugs with the risk of breast cancer, except for significant increases in the risk of breast cancer among patients who had used fertility drugs for >6 months.
journal_name
Clin Breast Cancerjournal_title
Clinical breast cancerauthors
Taheripanah R,Balash F,Anbiaee R,Mahmoodi M,Akbari Sene Adoi
10.1016/j.clbc.2018.03.003subject
Has Abstractpub_date
2018-10-01 00:00:00pages
395-399issue
5eissn
1526-8209issn
1938-0666pii
S1526-8209(17)30455-Xjournal_volume
18pub_type
杂志文章abstract:BACKGROUND:Volume displacement techniques that use remnant breast tissue are useful in reconstructive procedures after partial mastectomy. The authors analyzed the oncologic results of volume displacement surgery after partial mastectomy and their associations with various clinicopathologic factors. PATIENTS AND METHO...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2016.06.018
更新日期:2017-02-01 00:00:00
abstract:INTRODUCTION:Ensuring guideline-concordant cancer care is a Department of Veterans Affairs (VA) priority, especially as the number of breast cancer patients at VA medical centers (VAMCs) grows. We assessed the utilization and clinical impact of the 21-gene Recurrence Score test, which predicts 10-year risk of breast ca...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2017.11.018
更新日期:2018-04-01 00:00:00
abstract:INTRODUCTION:The purpose of this study was to evaluate the added value of breast magnetic resonance imaging (MRI) in preoperative diagnosis of ductal carcinoma in situ (DCIS). We reviewed our institution database of 3499 consecutive patients treated for breast cancer. PATIENTS AND METHODS:A total of 362 patients with ...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2016.12.007
更新日期:2017-06-01 00:00:00
abstract:UNLABELLED:The current study examined the impact of re-excision and residual disease on local recurrence after breast conservation treatment for patients with negative margins. Patients with residual disease on re-excision had a higher local recurrence rate than other patients. However, with reasonably low local recurr...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2011.08.003
更新日期:2011-12-01 00:00:00
abstract::Fulvestrant, an estrogen receptor antagonist that downregulates the estrogen receptor but has no known agonist effects, has been evaluated in 2 randomized trials involving postmenopausal women with hormone receptor-positive, progressive advanced-stage breast cancer after disease progression with antiestrogen therapy. ...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/cbc.2005.s.009
更新日期:2005-04-01 00:00:00
abstract:BACKGROUND:Medical isotopes are required for sentinel node lymphoscintigraphy in breast cancer, but are in critical shortage. Our center uses a modification of the standard SC, called CRC, that has been shown to require less medical isotope for the same procedure. Our objective was to determine if there was a significa...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2014.07.006
更新日期:2015-02-01 00:00:00
abstract:BACKGROUND:Radiation therapy (RT) is often delivered after lumpectomy for women with breast cancer. A common perceived side effect of RT is fatigue, yet its exact effect on activity levels and sleep is unknown. In this study we analyzed the change in activity levels and sleep using an activity tracking device before, d...
journal_title:Clinical breast cancer
pub_type: 临床试验,杂志文章
doi:10.1016/j.clbc.2017.08.009
更新日期:2018-02-01 00:00:00
abstract:BACKGROUND:Postmenopausal women with osteoporosis had a 66% relative risk reduction for invasive breast cancer over 8 years of raloxifene therapy in the randomized, placebo-controlled 4-year MORE (Multiple Outcomes of Raloxifene Evaluation) trial and the CORE (Continuing Outcomes Relevant to Evista) trial, a 4-year fol...
journal_title:Clinical breast cancer
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.3816/CBC.2009.n.008
更新日期:2009-02-01 00:00:00
abstract:UNLABELLED:Analysis of magnetic resonance imaging-guided breast biopsies yielding high-risk histopathologic features at a single institution found an overall upstage rate to malignancy of 14% at surgical excision. All upstaged lesions were associated with atypical ductal hyperplasia. Flat epithelial atypia and atypical...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2014.12.005
更新日期:2015-06-01 00:00:00
abstract:BACKGROUND:We aimed to evaluate the incidence of acute toxicity in a 3-week accelerated radiation therapy (RT) schedule with a concomitant boost compared with the 6.5-week conventional schedule with a sequential boost for early-stage, node-negative breast cancer. MATERIALS AND METHODS:This study included the first 50 ...
journal_title:Clinical breast cancer
pub_type: 杂志文章,随机对照试验
doi:10.1016/j.clbc.2011.09.002
更新日期:2012-02-01 00:00:00
abstract:BACKGROUND:The study aimed to evaluate the feasibility and reliability of ultrasound-guided vacuum-assisted breast biopsy (US-VABB) for sampling of microcalcifications indicative of cancer when stereotactic vacuum-assisted breast biopsy cannot be performed because of reasons such as thin breast tissue, insufficient thi...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2018.12.002
更新日期:2019-04-01 00:00:00
abstract::Currently, the interest in cognitive functioning following chemotherapy is rapidly expanding as is reflected in a growing number of published studies on this topic. Although most studies are indicative of cognitive deficits after chemotherapy, definite conclusions on the role of chemotherapy on cognitive function can ...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/cbc.2002.s.020
更新日期:2002-12-01 00:00:00
abstract:PURPOSE:To evaluate, in a series of early breast cancer (BC) patients treated with hypofractionated adjuvant radiotherapy (RT), whether N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I assay measurements can predict acute clinical or preclinical cardiotoxicity. PATI...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2020.09.005
更新日期:2020-09-10 00:00:00
abstract:INTRODUCTION:The purpose of the study was to determine predictors of recurrence for patients treated with neoadjuvant chemotherapy (NAC) and mastectomy according to the use of postmastectomy radiation therapy (PMRT). PATIENTS AND METHODS:An analysis of 161 clinically staged T1 to T3/N0 to N3 patients treated with NAC ...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2014.09.012
更新日期:2015-04-01 00:00:00
abstract:PURPOSE:The purpose of this study is to determine the response, tolerability, and long-term outcome of a neoadjuvant platinum-containing regimen for locally advanced breast cancer (LABC) and to search for a correlation between pathologic complete response (pCR) and predefined biomarkers in this cohort. PATIENTS AND ME...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2009.n.027
更新日期:2009-08-01 00:00:00
abstract:UNLABELLED:This is a retrospective study on 40 breast cancer patients, of which 20 have bone metastases, 10 have visceral metastases, and 10 have no evidence of disease, aimed at evaluating the role of CXCR4 and the RANK/RANKL/OPG system to predict bone metastases. CXCR4 expression, alone or in combination with RANK, i...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2011.05.001
更新日期:2011-12-01 00:00:00
abstract:BACKGROUND:There is no sufficient evidence to establish a standard of care for patients with brain metastases (BM) from HER2+ breast cancer (BC). The aim of this study was to assess the impact of local and systemic treatments on the outcome of patients diagnosed with BM from HER2+ BC over a period of 10 years, from 200...
journal_title:Clinical breast cancer
pub_type: 杂志文章,多中心研究
doi:10.1016/j.clbc.2019.05.006
更新日期:2019-08-01 00:00:00
abstract::Sentinel lymph node dissection (SLND) is a minimally invasive technique to stage axillary lymph nodes in breast cancer. The complications associated with SLND are minimal, especially when compared to routine axillary lymph node dissection (ALND), and it can be performed with an overall identification rate of greater t...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/CBC.2000.n.010
更新日期:2000-07-01 00:00:00
abstract:BACKGROUND:Nipple-sparing mastectomies (NSMs) preserve the intact nipple, including nipple duct orifices. Retained orifices might remain patent and communicate with the underlying reconstruction. We report the incidence and outcomes of nipple discharge after NSM in pregnant and nonpregnant women. PATIENTS AND METHODS:...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2019.03.003
更新日期:2019-08-01 00:00:00
abstract::The histopathologic subtypes of breast cancer, including invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), differ in terms of risk factors, progression, and response to treatment. The PubMed/Medline, Web of Science, and Scopus databases were searched up to February 2020 for published studies on the...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.1016/j.clbc.2020.03.007
更新日期:2020-08-01 00:00:00
abstract::Neoadjuvant chemotherapy has been employed increasingly in operable breast cancer during recent years. Several randomized trials showed that the chances of breast conserving therapy are being enhanced, and that survival was not compromised by primary systemic therapy compared to adjuvant treatment. Apart from the surg...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/cbc.2004.n.039
更新日期:2004-12-01 00:00:00
abstract::Post-breast cancer treatment-related angiosarcomas were first observed in lymphedematous extremities after mastectomy and are now being reported with increasing frequency after lumpectomy and radiation. A case history is presented of a BRCA2 carrier who had a postmastectomy chest wall angiosarcoma but had neither ther...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2008.n.066
更新日期:2008-12-01 00:00:00
abstract:BACKGROUND:Causes of racial disparities in breast cancer survival remain unclear. This study assesses overall survival (OS) after diagnosis between black and white women and examines factors that might correlate with this disparity. PATIENTS AND METHODS:Data were obtained from the Medical College of Georgia Tumor Regi...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2010.n.008
更新日期:2010-02-01 00:00:00
abstract::Tamoxifen reduced the risk of invasive breast cancer by 49% among women at increased risk for breast cancer in the Breast Cancer Prevention Trial P-1, and raloxifene reduced breast cancer incidence by more than 70% in the Multiple Outcomes of Raloxifene Evaluation osteoporosis trial. These findings led the National Su...
journal_title:Clinical breast cancer
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.3816/CBC.2002.n.020
更新日期:2002-06-01 00:00:00
abstract::Trastuzumab improves survival outcomes for patients with HER2-positive (HER2+) breast cancer, yet not all such women receive this important therapy. Trastuzumab was approved by the US Food and Drug Administration in 1998 and the European Medicines Agency in 2000 as treatment for HER2+ metastatic breast cancer (MBC). O...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.1016/j.clbc.2018.01.006
更新日期:2018-04-01 00:00:00
abstract:BACKGROUND:Recent studies have shown that breast cancer detected by screening has a more favorable prognosis than interval breast cancer. To further understand the biologic significance of this finding, we investigated the association of disease recurrence, local and distant, with the method of detection of the primary...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2008.n.014
更新日期:2008-04-01 00:00:00
abstract::Traditionally in the treatment of primary breast cancer, axillary lymph node dissection (ALND) plays an important role. However, a substantial and increasing percentage of patients appear to have no nodal involvement and have been subjected to ALND unnecessarily. The first reason to perform an ALND is axillary nodal s...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/cbc.2002.n.034
更新日期:2002-12-01 00:00:00
abstract:PURPOSE:In order to evaluate the feasibility of dose-dense docetaxel followed by dose-dense AC (doxorubicin/cyclophosphamide) as adjuvant chemotherapy for operable breast cancer, we conducted a phase II study. PATIENTS AND METHODS:In cohort 1, 28 patients received docetaxel 100 mg/m2 followed by doxorubicin 60 mg/m2 w...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2007.n.029
更新日期:2007-08-01 00:00:00
abstract:AIM:Our study was to investigate the heterogeneity of estrogen receptor (ER) expression among tumor sites by using fluorine-18 ((18)F) fluoroestradiol (FES) positron-emission tomography-computed tomography (PET-CT) imaging. METHODS:Thirty-two breast cancer patients underwent both (18)F-FES and (18)F fluorodeoxyglucose...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2013.02.012
更新日期:2013-10-01 00:00:00
abstract:BACKGROUND:Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer. PATIENTS AND METHODS:Patients received bortezomib...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2010.n.061
更新日期:2010-12-01 00:00:00